Physician profile
Jonathan Balagna
NPI 1871932442
$15,607.67
in general payments reported to CMS, 2019-2025
19 companies · $790 in 2025
The $790 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,653 · 2020: $2,937 · 2021: $1,664 · 2022: $3,519 · 2023: $1,079 · 2024: $2,965 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,124 · Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,124.47 |
| Food and Beverage | $709.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,831.70 | 2019-2024 | |
| Philips North America LLC | $2,965.97 | 2021-2024 | (Br0) Coronary Atherectomy, (Bq9) Coronary Ivus, (P84) Igt Devices Systems |
| Medtronic Vascular, INC. | $2,685.59 | 2020 | |
| Abbott Laboratories | $2,190.91 | 2022-2025 | Xience Skypoint |
| Edwards Lifesciences Corporation | $1,556.27 | 2021 | |
| Medtronic, INC. | $1,297.02 | 2020-2025 | Venaseal, Onyx Frontier |
| Abiomed | $776.02 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.24 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.41 | 2021-2022 | |
| Terumo Medical Corporation | $33.22 | 2022-2025 | Azur Cx Detachable |
| Amarin Pharma, INC. | $33.19 | 2019 | |
| Inari Medical, INC. | $20.57 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $17.22 | 2023 | Xarelto |
| Lantheus Medical Imaging, INC. | $15.43 | 2023 | Definity |
| W. L. Gore & Associates, INC. | $13.35 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $13.31 | 2022 | |
| Cardiovascular Systems INC. | $13.08 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Balagna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.